Strategy
Small Molecules, Big Opportunities
Led by an experienced team of biotechnology and business leaders, Sunesis is dedicated to becoming a fully integrated pharmaceutical company. We are committed to discovering, developing, and commercializing important medicines for the treatment of cancer. We believe that the medicines we are bringing forth have incredible potential to improve health care, and to allow us to reinvest in the business and in future programs.
State of the Business
Founded on the basis of a unique small molecule discovery platform, Sunesis' integrated research and development organization has expanded to include Clinical Operations, Translational Research, Clinical Science, Biometrics and Regulatory Affairs/Quality Assurance. The company now has multiple programs at various stages of development ranging from Discovery to Phase 2.
Future Growth
Although the company's internal programs are currently exclusively focused on oncology, Sunesis has successfully applied its platform to identify lead molecules in additional therapeutic areas in collaboration with other pharmaceutical companies. Discovery-stage collaborations continue to provide a means of extending Sunesis' portfolio outside of oncology while providing funding to help advance internal programs to significant value-added milestones. Sunesis seeks ultimately to commercialize its own products within the U.S. while retaining a robust research organization that can continue to bring innovative medicines forward.
